Biokosmes Srl – FDA 483, Dec 2, 2022
An FDA inspection of Biokosmes Srl, an OTC drug manufacturer in Bosisio Parini, Italy, revealed significant deficiencies across multiple areas of its operations. The firm failed to ensure proper identity testing of components, lacked adequate controls for preventing microbial contamination, and operated with unsuitable facility conditions for raw material weighing. Additionally, issues were noted in batch record keeping, computer system security, laboratory controls, and the overall adherence to quality control unit procedures.
ID · 5f4e89ba-3415-4e43-b4a4-11a1fda638f5
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.